ArticlePediatric nephrology (Berlin, Germany)2012
Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil.
Article in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP).The Cochrane database of systematic reviews · 2015Pooled it
- Therapy for kidney vasculitis in children during the acute phase and maintenance: updates and insights from new adult therapies.Pediatric nephrology (Berlin, Germany) · 2026Review
- Advances in multi-omics and therapeutic studies of Henoch-Schönlein purpura.Italian journal of pediatrics · 2025Review
- IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.Journal of clinical medicine · 2024Review
- Proanthocyanidins: A novel approach to Henoch‑Schonlein purpura through balancing immunity and arresting oxidative stress via TLR4/MyD88/NF‑κB signaling pathway (Review).Experimental and therapeutic medicine · 2023Review
- Interventions for preventing and treating kidney disease in IgA vasculitis.The Cochrane database of systematic reviews · 2023Review
- Early clinical course of biopsy-proven IgA vasculitis nephritis.BMC pediatrics · 2022Article
- Mycophenolate Mofetil for Severe IgA Vasculitis Nephropathy in Children: An Observational Study.Kidney medicine · 2022Article
- Leflunomide therapy for IgA vasculitis with nephritis in children.BMC pediatrics · 2021Article
- Management of IgA Vasculitis with Nephritis.Paediatric drugs · 2021Review
- Consensus evidence-based recommendations for treat-to-target management of immunoglobulin A vasculitis.Therapeutic advances in musculoskeletal disease · 2021Review
- Clinical outcome in pediatric refractory gastrointestinal Henoch-Schönlein purpura treated with mycophenolate mofetil.European journal of pediatrics · 2020Article
- IgA Vasculitis: Genetics and Clinical and Therapeutic Management.Current rheumatology reports · 2018Review
- Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring.Pediatric nephrology (Berlin, Germany) · 2018Article
- Mycophenolate mofetil for the treatment of Henoch-Schönlein purpura nephritis; current knowledge and new concepts.Journal of nephropathology · 2017Article
- Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- A single-center analysis of Henoch-Schonlein purpura nephritis with nephrotic proteinuria in children.Pediatric rheumatology online journal · 2017Article
- The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.Pediatric nephrology (Berlin, Germany) · 2017Review
- Treatment of Henoch Schonlein nephritis; new trends.Journal of nephropathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHenoch-Schönlein purpura (HSP) can progress to Henoch-Schönlein purpura nephritis (HSPN), and the most effective management remains unclear. Our aim was to evaluate the efficacy of mycophenolate mofetil (MMF) for treating pediatric patients with HSPN and nephrotic-range proteinuria.
methodsTwelve children, seven boys and five girls, mean age 8.33 (range 6-12) years at the time of HSPN diagnosis with nephrotic-range proteinuria, were treated with MMF. All patients failed steroid treatment, and mean proteinuria at the time of MMF initiation was 5.6 g/d. MMF dosage ranged from 20 to 25 mg/kg per day. Patients also received an angiotensin-converting enzyme inhibitor (cliazapril) at MMF initiation. Mean follow-up was 3.9 (range 2.3-5.5) years.
resultsAll patients responded to MMF at a mean of 2.5 (range 1-4 months). Among the 12 patients, MMF was administered for 10 months in five, 12 months in six, and 15 months in one. At last follow-up, all patients had negative proteinuria and normal renal function, and no relapses were noted. No serious adverse effects of MMF were noted in any patient.
conclusionMMF is useful for treating pediatric patients with HSPN and nephrotic-range proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.